2012 update in the treatment of prolactinomas

Annales d'Endocrinologie

Volumn 73, Issue 2, 2012, Pages 90-98

  Maiter, Dominique ^a   Primeau, Vanessa ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; PERGOLIDE; PROGESTERONE; PROLACTIN; QUINAGOLIDE; TEMOZOLOMIDE;

ANOVULATION; ARTICLE; ASYMPTOMATIC DISEASE; CANCER CONTROL; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM METASTASIS; CONGENITAL MALFORMATION; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EATING DISORDER; ECHOCARDIOGRAPHY; FEMALE INFERTILITY; FETUS DEVELOPMENT; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GLIOMA; HEART DISEASE; HORMONAL REGULATION; HUMAN; HYPERPROLACTINEMIA; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; LONG TERM CARE; LOW DRUG DOSE; NOSE CONGESTION; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL CONTRACEPTION; PATIENT COMPLIANCE; PATIENT MONITORING; PERIMETRY; PERIPHERAL VASOSPASM; POSTOPERATIVE CARE; PREMATURE LABOR; PROLACTIN BLOOD LEVEL; PROLACTINOMA; RECURRENT DISEASE; REMISSION; SPONTANEOUS ABORTION; SURVIVAL TIME; SYMPTOM; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR VOLUME; VASOSPASM;

DOPAMINE AGONISTS; ENDOCRINOLOGY; ERGOLINES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEUROSURGICAL PROCEDURES; PITUITARY NEOPLASMS; PREGNANCY; PROLACTIN; PROLACTINOMA;

EID: 84860915207     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ando.2012.03.024     Document Type: Article

References (80)

1. Daly A.F., Rixhon M., Adam C., Dempegioti A., Tichomirowa M.A., Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege Belgium. J Clin Endocrinol Metab 2006, 91:4769-4775.
2. Fernandez A., Karavitaki N., Wass J.A.H. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol 2010, 72:377-382.
3. Raappana A., Koivukangas J., Ebeling T., Pirilä T. Incidence of pituitary adenomas in Northern Finland in 1992-2007. J Clin Endocrinol Metab 2010, 95:4268-4275.
4. Schlechte J.A. Clinical practice. Prolactinoma. N Engl J Med 2003, 349:2035-2041.
5. Molitch M.E. Prolactinoma. Pituitary 2002, Blackwell Science Inc, p. 455-95. 2nd ed. M. Melmed (Ed.).
6. Delgrange E., Trouillas J., Maiter D., Donckier J., Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 1997, 82:2102-2107.
7. Casanueva F.F., Molitch M.E., Schlechte J.A., Abs R., Bonert V., et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 2006, 65:265-273.
8. Gillam M.P., Molitch M.E., Lombardi G., Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006, 27:485-534.
9. Melmed S., Casanueva F.F., Hoffman A.R., Kleinberg D.L., Montori V.M., Schlechte J.A., et al. Diagnosis and treatment of hyperprolactinemia. An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011, 96:273-288.
10. Melmed S., Kleinberg D. Anterior pituitary. Williams textbook of Endocrinology 2009, Saunders Elsevier, Philadelphia, p. 185-261. 11th ed. H.M. Kronenberg, S. Melmed, K.S. Polonsky, P.R. Larsen (Eds.).
11. Karavitaki N., Thanabalasingham G., Shore H.C.A., Trifanescu R., Ansorge O., et al. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma. Clin Endocrinol 2006, 65:524-529.
12. Brochier S., Galland F., Kujas M., Parker F., Gaillard S., Raftopoulos C., et al. Factors predicting relapse of non-functioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur J Endocrinol 2010, 163:193-200.
13. Corenblum B., Donovan L. The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 1993, 59:671-673.
14. Testa G., Vegetti W., Motta T., Alagna F., Blanchedi D., Carlucci C., et al. Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 1998, 58:69-73.
15. Delgrange E., Duprez T., Maiter D. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy. Clin Endocrinol 2006, 64:456-462.
16. Deepak D., Daousi C., Javadpour M., MacFarlane I.A. Macroprolactinomas and epilepsy. Clin Endocrinol 2007, 66:503-507.
17. Thorner M.O., McNeilly A.S., Hagan C., Besser G.M. Long-term treatment of galactorrhea and hypogonadism with bromocriptine. BMJ 1974, 2:419-422.
18. Webster J. Clinical management of prolactinomas. Baillieres Clin Endocrinol Metab 1999, 13:395-408.
19. Webster J., Piscitelli G., Polli A., Ferrari C.I., Ismail I., Scanlon M.F. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994, 331:904-909.
20. Verhelst J., Abs R., Maiter D., Van den Bruel A., Vandeweghe M., et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999, 84:2518-2522.
21. Delgrange E., Maiter D., Donckier J. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol 1996, 134:454-456.
22. Barlier A., Jacquet P. Quinagolide - a valuable treatment option for hyperprolactinaemia. Eur J Endocrinol 2006, 154:187-195.
23. Delgrange E., Daems T., Verhelst J., Abs R., Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 2009, 160:747-752.
24. Delgrange E., Maiter D. Macroadénome hypophysaire à prolactine : traitement par la cabergoline. Med Clin Endocrinol Diab 2004, 4-9.
25. Colao A., Di Sarno A., Landi M.L., Scavuzzo F., Cappabianca P., et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000, 85:2247-2252.
26. Corsello S.M., Ubertini G., Altomare M., Lovicu R.M., Migneco M.G., et al. Giant prolactinomas in men: efficacity of cabergoline treatment. Clin Endocrinol 2003, 58:662-670.
27. Dekkers O.M., Lagro J., Burman P., Jorgensen J.O., Romijn J.A., Pereira A.M. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 2010, 95:43-51.
28. Colao A., Di Sarno A., Cappabianca P., Di Somma C., Pivonello R., Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 2003, 349:2023-2033.
29. Kharlip J., Salvatori R., Yenokyan G., Wand G.S. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 2009, 94:2428-2436.
30. Klibanski A. Dopamine agonist therapy in prolactinomas: when can treatment be discontinued?. J Clin Endocrinol Metab 2009, 94:2247-2249.
31. Schlechte J.A. Long-term management of prolactinomas. J Clin Endocrinol Metab 2007, 92:2861-2865.
32. Schade R., Andersohn F., Suissa S., Haverkamp W., Garde E. Dopamine agonists and the risk of cardiac valve regurgitation. N Engl J Med 2007, 356:29-38.
33. Zanettini R., Antonini A., Gatto G., Gentile R., Tesei S., Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007, 356:39-46.
34. Van Camp G., Flamez A., Cosyns B., et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004, 363:1179-1183.
35. Roth B.L. Drugs and valvular heart disease. N Engl J Med 2007, 356:6-9.
36. Igbokwe R., Jolas T., Waters A., Webster J. Differential effects of dopamine agonists at D2s and 5HT2B receptors. Program Br Endocr Soc 2009, 19:251. [abstract].
37. Lancellotti P., Livadariu E., Markov M., Daly A.F., Burlacu M.C., et al. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 2008, 159:1-5.
38. Bogazzi F., Buralli S., Manetti L., Raffaelli V., Cigni T., et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract 2008, 62:1864-1869.
39. Vallette S., Serri K., Rivera J., Santagata P., Delorme S., et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2009, 12:153-157.
40. Kars M., Delgado V., Holman E.R., Feelders R.A., Smit J.W.A., et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 2008, 93:3348-3356.
41. Colao A., Galderisi M., Di Sarno A., Pardo M., Gaccione M., et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab 2008, 93:3777-3784.
42. Wakil A., Rigby A., Clark A., Atkin S. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 2008, 159:11-14.
43. Nachtigall L.B., Valassi E., Lo J., et al. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol 2010, 72:53-58.
44. Herring N., Szmigielski C., Becher H., Karavitaki N., Wass J.A.H. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol 2009, 70:104-108.
45. Lafeber M., Stades A.M.E., Valk G.D., Cramer M.J., Teding van Berkhout F., Zalissen M.J. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinol 2010, 162:667-675.
46. Tan T., Cabrita I.Z., Hensman D., Grogono J., Dhillo W.S., et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol 2010, 73:369-374.
47. Kars M., Pereira A.M., Bax J.J., Romijn J.A. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur J Endocrinol 2008, 159:363-367.
48. Valassi E., Klibanski A., Biller B.M.K. Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 2010, 95:1025-1033.
49. Delgado V., Biermasz N.R., van Thiel S.W. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Clin Endocrinol 2012, 10.1111/j.1365-2265.2011.04326.x.
50. Martinkova J., Trejbalova L., Sasikova M., Benetin J., Valkovic P. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin Neuropharmacol 2011, 34:179-181.
51. Davie M. Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. J Neuropsychiatry Clin Neurosci 2007, 19:473-474.
52. Ono M., Miki N., Kawamata T., Makino R., Amano K., et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 2008, 93:4721-4727.
53. Molitch M. The cabergoline-resistant prolactinoma patient: new challenges. J Clin Endocrinol Metab 2008, 93:4643-4645.
54. Di Sarno A., Landi M.L., Cappabianca P., Di Salle F., Rossi F.W., et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 2001, 86:5256-5261.
55. Brada M., Jankowska P Radiotherapy for pituitary adenomas. Endocrinol Metab Clin North Am 2008, 37:263-275.
56. Kars M., Roelfsema F., Romijn J.A., Pereira A.M. Malignant prolactinoma: Case report and review of the literature. Eur J Endocrinol 2006, 155:523-534.
57. Kaltsas G.A., Nomikos P., Kontogeorgos G., Buchfelder M., Grossman A.B. Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 2005, 90:3089-3099.
58. Hagen C., Schroeder H.D., Hansen S., Hagen C., Andersen M. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy, Case Report. Eur J Endocrinol 2009, 161:631-637.
59. Syro L.V., Ortiz L.D., Scheithauer B.W., Lloyd R., Lau Q., Gonzalez R., et al. Treatment of pituitary neoplasms with temozolomide: a review. Cancer 2011, 117:454-462.
60. Raverot G., Sturm N., de Fraipont F., Muller M., Salenave S., Caron P., et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: A French multicenter experience. J Clin Endocrinol Metab 2010, 95:4592-4599.
61. Losa M., Mortini P., Barzaghi R., Gioia L., Giovanelli M. Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 2002, 87:3180-3186.
62. Amar A.P., Couldwell W.T., Chen J.C., Weiss M. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J Neurosurg 2002, 97:307-314.
63. Hamilton D.K., Vance M.L., Boulos P.T., Laws E.R. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 2005, 8:53-60.
64. Kreutzer J., Buslei R., Wallaschofski H., Hofmann B., Nimsky C., Fahlbusch F., et al. Operative treatment of prolactinomas: indications and results in current consecutive series of 212 patients. Eur J of Endocrinol 2008, 158:11-18.
65. Raverot G., Wierinckx A., Dantony E., Auger C., Chapas G., et al. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a post-operative follow-up. J Clin Endocrinol Metab 2010, 95:1708-1716.
66. Webster J., Page M.D., Bevan J.S., Richards S.H., Douglas-Jones A.G., Scanlon M.F. Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests. Clin Endocrinol 1992, 36:35-44.
67. Massoud F., Serri O., Hardy J., Somma M., Beauregard H. Transsphenoidal adenomectomy for microprolactinomas: 10-20 years of follow-up. Surg Neurol 1996, 45:341-346.
68. Tyrrell J.B., Lamborn K.R., Hannegan L.T., Applebury C.B., Wilson C.B. Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results. Neurosurgery 1999, 44:254-261.
69. Primeau V., Maiter D. Clinical characteristics and prognostic factors in a cohort of 70 patients operated for prolactinoma. Ann Endocrinol 2011, 72:370.
70. Molitch M.E. Management of prolactinomas during pregnancy. J Reprod Med 1999, 44:1121-1126.
71. Turkalj P., Braun P., Krupp P. Surveillance of bromocriptine in pregnancy. JAMA 1982, 247:1589-1591.
72. Krupp P., Monka C. Bromocriptine in pregnancy: safety aspects. Wien Klin Wochensch 1987, 65:823-827.
73. Weil C. The safety of bromocriptine in hyperprolactinaemic female infertility: a literature review. Curr Med Res Opin 1986, 10:172-195.
74. Molitch M.E. Prolactinoma in pregnancy. Best Practice. Res Clin Endocrinol Metab 2011, 25:885-896.
75. Ricci E., Parazzini F., Motta T., Ferrari C.I., Colao A., Clavella A., et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002, 16:791-793.
76. Colao A., Abs R., Barcena D.G., Chanson P., Paulus W., Kleinberg D.L. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol 2008, 68:66-71.
77. Lebbe M., Hubinont C., Bernard P., Maiter D. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol 2010, 73:236-242.
78. Ono M., Miki N., Amano K., Kawamata T., Seki T., Makino R., et al. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas. J Clin Endocrinol Metab 2010, 95:2672-2679.
79. Stalldecker G., Mallea-Gil M.S., Guitelman M., Alfieri A., Ballarino M.C., et al. Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103 pregnancies and a review of the literature. Pituitary 2010, 13:345-350.
80. Jeffcoate W.J., Pound N., Sturrock N.D., Lambourne J. Long-term follow-up of patients with hyperprolactinaemia. Clin Endocrinol 1996, 45:299-303.